Leigh Purvis, director of Health Services Research at AARP Public Policy Institute, addresses the burdens of high prescription drug costs on Medicare beneficiaries.
Leigh Purvis, director of Health Services Research at AARP Public Policy Institute, addresses the burdens of high prescription drug costs on Medicare beneficiaries.
Transcript
How does the burden of high prescription drug costs among the Medicare population differ from the general population?
I think the biggest difference that we’re seeing in terms of high cost drugs for Medicare beneficiaries is that under Medicare Part D there is a lot of coinsurance which is where they are responsible for a percentage of the drug cost as opposed to a flat copayment, and that type of payment structure hasn’t stretched too other forms of insurance yet. So, we are seeing Part D beneficiaries being responsible for much more of the cost than we see in other forms of insurance.
How do Medicare beneficiaries usually handle being faced with the donut hole after coming employer-sponsored insurance, where they didn’t have to deal with it?
Unfortunately, we see a lot of people either walking away from the pharmacy counter or trying to find other ways of getting their prescription drugs which is a problem because they are obviously operating outside of the system or they’re not treating the conditions that need to be treated, and that can ultimately lead to higher health care costs down the road.
What impact do you see new treatments that are very effective, but very expensive, having on Medicare and patients?
I think both of them are being negatively affected. Innovation is great, but it’s only great if you can afford to use it and, unfortunately, that’s kind of the trade-off that we are facing right now and we want to make sure that we are having access to these innovative therapies. The Medicare program is a tax-payer funded program and the more it’s spending on these types of products, the more tax payers are spending on these types of products, the more beneficiaries that are being asked to spend on these types of products. Unfortunately, I think about these groups, MedPack included, that have come to the conclusion that it’s really unsustainable. It pushes us to a precipice where people can’t access the drugs that they need.
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
Covered Preventive Services at Risk: V-BID Summit Breaks Down the Braidwood v Becerra Case
March 20th 2024For more than a decade, certain high-value preventive care services have been covered at no cost to patients under the Affordable Care Act, but a current legal challenge has the coverage at risk.
Read More